Friday 6 November 2026 Export RXRX’s income statement to Excel — free account

Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.

Revenue: +258.5%
EPS: +39.1%
Free cash flow: +33.8%
Total debt: −99.2%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

3.59 0.09 +2.57%

Follow RXRX

Alert me

Market cap: $2.2B
P/E: 0.0×
Fwd P/E: −4.6×
Dividend yield: —
F-score: 3/9
Altman Z: 0.37
Beneish M: −1.72
Dividend safety: n/a

Overview

Recursion Pharmaceuticals, Inc. (RXRX) Current ratio

Alert me on Current ratio

Recursion Pharmaceuticals, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 5.0×, down 0.5× from fiscal 2025 (5.5×). Over the past ten years it has ranged from 3.8× (fiscal 2024) to 11.7× (fiscal 2020); the current reading is higher than 27% of that period. That is in line with the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RXRX/current-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Recursion Pharmaceuticals, Inc. current ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RXRX/metrics/current-ratio">Recursion Pharmaceuticals, Inc. (RXRX) current ratio — stockrow.com</a></p>

Period	Current ratio	Change
FY2025	5.5×	44.44%
FY2024	3.8×	(18.98%)
FY2023	4.7×	(17.25%)
FY2022	5.7×	0.00%
FY2022	5.7×	(50.41%)
FY2021	11.5×	0.00%
FY2021	11.5×	(0.64%)
FY2020	11.5×	(1.13%)
FY2020	11.7×	2.07%
FY2019	11.4×	0.00%

Period	Current ratio	Change
Sep 2026	5.0×	(0.44%)
Jun 2026	5.0×	(7.99%)
Mar 2026	5.5×	(0.59%)
Dec 2025	5.5×	19.53%
21 more quarters	Free account

Against its own ten years

Low 3.8× High 11.7×

Ten-year median 11.4×

Current reading's percentile 27

Company	Current ratio
PVLA Palvella Therapeutics, Inc. compare	21.2×
MBX MBX Biosciences, Inc. compare	18.1×
PHVS Pharvaris N.V. compare	11.9×
CLDX Celldex Therapeutics, Inc. compare	11.8×
NAMS NewAmsterdam Pharma Company N.V. compare	11.8×
ADMA ADMA Biologics Inc compare	6.0×
VCEL Vericel Corporation compare	5.1×
RXRX Recursion Pharmaceuticals, Inc.	5.0×
BHVN Biohaven Ltd. compare	3.1×
Biotechnology industry median	4.9×
Healthcare sector median	3.1×
Market median	1.6×

What Current ratio is

Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.

Current Assets (Total) ÷ Current Liabilities (Total)

The full definition of Current ratio →

Recursion Pharmaceuticals, Inc. (RXRX) Current ratio

Current ratio, annual

Annual newest first

Quarterly newest first

Against its own ten years

Current ratio against peers

What Current ratio is

More on RXRX

Current ratio, annual

Annual newest first

Quarterly newest first

Against its own ten years

Current ratio against peers

What Current ratio is

More on RXRX

Stockrow Weekly